Izumi, Takahiko
Maruko, Ichiro http://orcid.org/0000-0001-5647-6372
Kawano, Taizo
Sakaihara, Manabu
Iida, Tomohiro
Funding for this research was provided by:
JSPS KAKENHI (20K09781)
Article History
Received: 10 June 2021
Revised: 29 July 2021
Accepted: 10 August 2021
First Online: 19 August 2021
Declarations
:
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the Institutional Review Board of the Tokyo Women’s Medical University and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.
: Izumi: Personal fees from Novartis (Japan), Senju (Japan), outside the submitted work.Maruko: Grants from JSPS KAKENHI (Grant Number JP 20K09781), grants and personal fees from Alcon Pharma (Japan), personal fees from Bayer Yakuhin, Ltd. (Japan), personal fees from Santen Pharmaceutical Inc. (Japan), personal fees from Alcon Japan, Ltd., personal fees from Topcon Co., Ltd. (Japan), personal fees from Senju Pharmaceutical Co. (Japan), Ltd., personal fees from NIDEK Co., Ltd. (Japan), outside the submitted work. Maruko has a patent Peripheral retinal imaging system pending.Kawano: Personal fees from Senju (Japan), outside the submitted work.Sakaihara: Employee by Topcon Corp.Iida.: Consultant- Bayer (Japan), Chugai (Japan); Research support from Topcon (Japan); Personal fees from Bayer (Japan), Novartis (Japan), Nidek (Japan), Kowa (Japan), Canon (Japan), Topcon (Japan), Santen (Japan), Senju (Japan), Alcon (Japan), HOYA (Japan), AMO (Japan), Pfizer (Japan), Otsuka (Japan), JFC (Japan), Nikon (Japan), outside the submitted work. Iida has a patent Peripheral retinal imaging system pending.